浏览全部资源
扫码关注微信
1.天津中医药大学研究生院,天津 301617
2.天津中医药大学第二附属医院临床药理中心,天津 300250
3.天津中医药大学第一附属医院国医堂,天津 300193
Published:30 August 2023,
Received:22 February 2023,
Revised:29 June 2023,
扫 描 看 全 文
刘凡琪,王婧媛,李楠等.复方曲肽注射液对细胞色素P450酶活性的体内外影响 Δ[J].中国药房,2023,34(16):1972-1978.
LIU Fanqi,WANG Jingyuan,LI Nan,et al.Effects of Compound troxerutin and poreine cerebroside injection on cytochrome P450 enzyme in vivo and in vitro[J].ZHONGGUO YAOFANG,2023,34(16):1972-1978.
刘凡琪,王婧媛,李楠等.复方曲肽注射液对细胞色素P450酶活性的体内外影响 Δ[J].中国药房,2023,34(16):1972-1978. DOI: 10.6039/j.issn.1001-0408.2023.16.10.
LIU Fanqi,WANG Jingyuan,LI Nan,et al.Effects of Compound troxerutin and poreine cerebroside injection on cytochrome P450 enzyme in vivo and in vitro[J].ZHONGGUO YAOFANG,2023,34(16):1972-1978. DOI: 10.6039/j.issn.1001-0408.2023.16.10.
目的
2
考察复方曲肽注射液对细胞色素P450(CYP450)酶活性的体内外影响。
方法
2
将人肝微粒体与复方曲肽注射液(体积分数0.05%~10%)和CYP1A2、CYP2B6、CYP2C8、CYP2C9、CYP2C19、CYP2D6、CYP3A4的特异性探针底物共孵育30 min,采用超高效液相色谱-串联质谱(UPLC-MS/MS)技术检测相应代谢产物的生成量,并计算半数抑制浓度(IC
50
);将人原代肝细胞与复方曲肽注射液(体积分数0.05%~10%)或CYP1A2、CYP2B6、CYP3A4阳性诱导剂共孵育48 h后,采用实时荧光定量聚合酶链式反应法测定上述酶mRNA的相对表达量(即诱导倍数)。将雄性SD大鼠随机分为对照组(生理盐水+CYP1A2、CYP2B6、CYP2C8、CYP2C9、CYP2C19、CYP2D6、CYP3A4探针底物8、2、1、1、10、10、8 mg/kg)和实验组(复方曲肽注射液0.9 mL/kg+CYP1A2、CYP2B6、CYP2C8、CYP2C9、CYP2C19、CYP2D6、CYP3A4探针底物8、2、1、1、10、10、8 mg/kg),每组6只,采用Cocktail探针药物法,以UPLC-MS/MS技术为手段,检测各探针底物的药动学参数。
结果
2
经0.05%~10%复方曲肽注射液处理后,人肝微粒体中CYP2B6、CYP2C8、CYP2C19的活性无明显变化,未能拟合出IC
50
;CYP1A2、CYP2C9、CYP2D6、CYP3A4的IC
50
分别为419.90%、97.78%、176.00%、19.42%;经0.05%~10%复方曲肽注射液处理后,人原代肝细胞(批号MHK)中CYP3A4 mRNA的平均诱导倍数为4.88(且有2个浓度点的平均诱导倍数>2);经复方曲肽注射液干预后,CYP2C8、CYP2C9、CYP2C19底物的AUC
0-
t
、AUC
0-∞
均显著升高,CYP2C8、CYP2C19底物的CL均显著降低,CYP2C9酶底物的
t
1/2
显著延长(
P
<0.05)。
结论
2
复方曲肽注射液对人肝微粒中CYP1A2、CYP2B6、CYP2C8、CYP2C9、CYP2C19、CYP2D6、CYP3A4活性无明显的体外抑制作用,对人原代肝细胞中CYP3A4 mRNA的表达有体外诱导作用,对大鼠CYP2C8、CYP2C9、CYP2C19活性有体内抑制作用。
OBJECTIVE
2
To investigate the effects of Compound troxerutin and poreine cerebroside injection on the activity of cytochrome P450 (CYP450) enzyme
in vivo
and
in vitro
.
METHODS
2
Human liver microsomes were incubated with Compound troxerutin and poreine cerebroside injection (volume fraction 0.05%-10%) and the specific probe substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 for 30 min. The production of corresponding metabolites was detected by ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), and the half inhibitory concentration (IC
50
) was calculated. The relative mRNA expression (i.e. induction multiple) of CYP450 enzyme was determined by real-time fluorescence quantitative PCR after human primary hepatocytes were incubated with Compound troxerutin and poreine cerebroside injection (volume fraction 0.05%-10%) or 3 positive inducers of CYP1A2, CYP2B6, CYP3A4 for 48 hours. Male SD rats were randomly divided into control group (normal saline+probe substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 8, 2, 1, 1, 10, 10, 8 mg/kg) and experimental group (Compound troxerutin and poreine cerebroside injection 0.9 mL/kg+probe substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 8, 2, 1, 1, 10, 10, 8 mg/kg), with 6 rats in each group. The pharmacokinetic parameters of probe substrates were detected by UPLC-MS/MS and Cocktail probe drug method.
RESULTS
2
After the treatment of 0.05%-10% Compound troxerutin and poreine cerebroside injection, the activities of CYP2B6, CYP2C8 and CYP2C19 in human liver microsomes had no significant change, and IC
50
could not be fitted; IC
50
of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 were 419.90%, 97.78%, 176.00%, 19.42%, respectively. After the treatment of 0.05%-10% Compound troxerutin and poreine cerebroside injection, the average induction multiple of CYP3A4 mRNA in human primary hepatocytes (No. MHK) was 4.88 (and the average induction multiples of 2 concentration points were higher than 2). After the treatment of Compound troxerutin and poreine cerebroside injection, AUC
0-
t
and AUC
0-∞
of CYP2C8, CYP2C9 and CYP2C19 substrates were increased significantly, CL of CYP2C8 and CYP2C19 substrates were decreased significantly, while
t
1/2
of CYP2C9 substrate was prolonged significantly (
P
<0.05).
CONCLUSIONS
2
Compound troxerutin and poreine cerebroside injection has no obvious inhibitory effect on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 in human liver microsomes
in vitro
, but can induce the mRNA expression of CYP3A4 in human primary hepatocytes
in vitro
, and can inhibit the activities of CYP2C8, CYP2C9 and CYP2C19 in rats
in vivo
.
复方曲肽注射液细胞色素P450酶抑制酶诱导药物相互作用
cytochrome P450enzyme inhibitionenzyme inductiondrug interaction
ZANGER U M,SCHWAB M. Cytochrome P450 enzymes in drug metabolism:regulation of gene expression,enzyme activities,and impact of genetic variation[J]. Pharmacol Ther,2013,138(1):103-141.
郭科,资晓宏,殷刚,等. 复方曲肽注射液治疗老年急性脑梗死临床疗效及对患者血清炎性因子的影响[J]. 中国老年学杂志,2021,41(18):3910-3913.
孙明,姜永宁,田威娜. 复方曲肽注射液对脑梗死患者微循环及血小板聚集性的影响[J]. 解放军预防医学杂志,2019,37(11):20-21.
冯霞. 复方曲肽注射液联合依达拉奉治疗老年急性脑梗死的疗效观察[J]. 中西医结合心脑血管病杂志,2021,19(19):3400-3403.
白金娟,田龙,张红利. 复方曲肽注射液联合降纤酶治疗急性脑梗死的临床研究[J]. 现代药物与临床,2020,35(2):247-251.
U.S. Food and Drug Administration(FDA),Center for Drug Evaluation and Research(CDER). In vitro drug interaction studies:cytochrome P450 enzyme- and transporter- mediated drug interactions guidance for industry [EB/OL]. [2023-02-20]. https://www.fda.gov/regulatory-information/ search-fda-guidance-documents/in-vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactionshttps://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions.
国家药品监督管理局药品审评中心.药物相互作用研究技术指导原则:试行[EB/OL].(2021-01-25)[2023-02-20]. https://www.cde.org.cn/main/news/viewInfoCommon/5a-15b727e605482c1cf594c689bb994bhttps://www.cde.org.cn/main/news/viewInfoCommon/5a-15b727e605482c1cf594c689bb994b.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use(ICH). Drug interaction studies M12[EB/OL]. [2023-02-20]. https://database.ich.org/sites/default/files/M12_Step1_draft_Guideline_2022_0524.pdfhttps://database.ich.org/sites/default/files/M12_Step1_draft_Guideline_2022_0524.pdf.
国家药典委员会.中华人民共和国药典:四部[M]. 2020年版.北京:中国医药科技出版社,2020:466-472.
强婷婷,李益萍,王肖龙. 生脉注射液体外对CYP450酶与转运体抑制作用的研究[J]. 中草药,2021,52(12):3568-3575.
卢元媛. 基于液相色谱质谱联用技术对复方中药艾可清化学成分及其调节细胞色素P450酶作用的研究[D]. 广州:广州中医药大学,2018.
DINGER,MEYER M R,MAURER H H. Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse[J]. Toxicol Lett,2014,230(1):28-35.
罗瑞芝,余斐斐,周大铮,等. 注射用益气复脉(冻干)对CYP450药物代谢酶1A2、2B6和3A4诱导作用的体外研究[J]. 药物评价研究,2018,41(3):417-421.
ZHANG J X,QI M J,SHI M Z,et al. Effects of Danhong injection,a traditional Chinese medicine,on nine cytochrome P450 isoforms in vitro[J]. Biomed Chromatogr,2019,33(4):e4454.
陈瑞,周维,张丽,等. 树豆酮酸A对人肝微粒体中5种常见细胞色素P450酶的体外抑制作用研究[J]. 中国药房,2021,32(2):195-200.
QIN Z F,JIA M M,YANG J,et al. Multiple circulating alkaloids and saponins from intravenous Kang-Ai injection inhibit human cytochrome P450 and UDP-glucuro-nosyltransferase isozymes:potential drug-drug interactions[J]. Chin Med,2020,15:69.
MARTIGNONI M,GROOTHUIS G M,KANTER R D. Species differences between mouse,rat,dog,monkey and human CYP-mediated drug metabolism,inhibition and induction[J]. Expert Opin Drug Metab Toxicol,2006,2(6):875-894.
0
Views
2
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution